P1, N=6, Not yet recruiting, Navigator Medicines

P1, N=48, Not yet recruiting, Navigator Medicines

Further in vitro investigations confirmed that human podocytes, exposed to TNFα donor plasma, demonstrated TNFR1 signaling driven injury profiles, a response that was ameliorated by infliximab. Our data provide evidence that monitoring plasma inflammation levels during donor management offers a window of opportunity to intervene and improve optimisation and quality of deceased donor organs.

P=N/A, N=45, Not yet recruiting, Hospices Civils de Lyon

The JSpA in this cohort demonstrated substantial disease burden, with frequent axial and peripheral involvement. Although 43.2% of patients achieved clinical remission, sustained remission off medication was observed in only 10.2%, reflecting the chronic disease course. Early diagnosis and optimized treatment strategies remain essential to improve outcomes.

This finding highlights the functional relevance of IMiD's inherent polypharmacology in circumventing primary resistance mechanisms at the cellular level. Together, our results identify the ARID2-containing PBAF complex as a critical vulnerability in resistant myeloma cells and provide a mechanistic rationale for designing combination strategies that co-target this complex, with the potential to enhance therapeutic efficacy by overcoming drug resistance.

In vivo experimental results demonstrated that oral administration of this IFX formulation in colitis-induced mice significantly reduced the levels of pro-inflammatory cytokines (TNF-α and IL-6) and myeloperoxidase (MPO), and effectively alleviated colonic tissue damage. This IFX formulation exhibits excellent potential for oral antibody delivery, with enhanced targeting efficiency and reduced systemic toxicity, thus promising to provide a novel clinically translatable strategy for IBD treatment.

P1/2, N=30, Not yet recruiting, Erasmus Medical Center

P=N/A, N=300, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

P2, N=150, Recruiting, Navigator Medicines, Inc.

The complementary activity of lirafugratinib and futibatinib against FGFR2 kinase domain mutations supports their sequential use, when precise resistance mutations are detected in patients.

P1/2, N=14, Active, not recruiting, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Trial completion date: Jun 2026 --> Feb 2027 | Trial primary completion date: Dec 2025 --> Jan 2027